Characteristic | Crude HR (95% CI) | P-value* (bivariatea) | Adjusted HR (95% CI) | P-value* (multivariablea) |
---|---|---|---|---|
Primary tumor location | ||||
Right vs. Left | 2.09 (1.31–3.33) | 0.002 | 1.55 (0.92–2.61) | 0.099 |
Age | ||||
>60 years vs. ≤ 60 | 0.77 (0.54–1.08) | 0.133 | 0.77 (0.53–1.13) | 0.180 |
Gender | ||||
Female vs. Male | 1.15 (0.80–1.64) | 0.449 | 1.11 (0.75–1.64) | 0.616 |
Stage at presentation | ||||
Stage IV vs. Stage I-III | 0.99 (0.66–1.49) | 0.965 | ||
Histologic grade | ||||
P/D or SRC vs. W/D or M/D | 5.37(2.24–12.87) | <0.001 | 3.06 (1.22–7.67) | 0.017 |
Presence of liver metastasis | ||||
Yes vs. No | 1.04 (0.73–1.50) | 0.816 | ||
Presence of lung metastasis | ||||
Yes vs. No | 0.87 (0.63–1.21) | 0.419 | ||
Presence of peritoneal metastasis | ||||
Yes vs. No | 2.53 (1.53–4.19) | <0.001 | 2.08 (1.19–3.63) | 0.010 |
Number of metastasized organs | ||||
≥ 2 vs. 1 | 1.11 (0.80–1.53) | 0.543 | ||
BRAF | ||||
Mutant vs. Wild-type | 3.56 (2.11–6.01) | <0.001 | 3.07 (1.73–5.46) | <0.001 |
PIK3CA | ||||
Mutant vs. Wild-type | 2.60 (0.95–7.11) | 0.062 |